Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.41 USD
+0.28 (1.63%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $17.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Income Statements
Fiscal Year end for Edgewise Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 114 | 72 | 43 | 17 | 0 |
Income After Depreciation & Amortization | -114 | -72 | -43 | -17 | 0 |
Non-Operating Income | 14 | 4 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -100 | -68 | -43 | -17 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -100 | -68 | -43 | -17 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -100 | -68 | -43 | -17 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -122 | -72 | -43 | -17 | 0 |
Depreciation & Amortization (Cash Flow) | -8 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -114 | -72 | -43 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 63.80 | 53.26 | 37.53 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.57 | -1.27 | -1.14 | NA | NA |
Diluted Net EPS (GAAP) | -1.57 | -1.26 | -1.14 | NA | NA |
Fiscal Year end for Edgewise Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 34.75 | 33.86 | 29.46 | 25.34 | 25.71 |
Income After SG&A, R&D, and Dept/Amort Expenses | -34.75 | -33.86 | -29.46 | -25.34 | -25.71 |
Non-Operating Income | 6.23 | 3.72 | 3.74 | 3.87 | 2.87 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -28.53 | -30.14 | -25.71 | -21.47 | -22.84 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -28.53 | -30.14 | -25.71 | -21.47 | -22.84 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -28.53 | -30.14 | -25.71 | -21.47 | -22.84 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 87.57 | 64.78 | 63.46 | 63.38 | 63.27 |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.47 | -0.41 | -0.34 | -0.36 |
Diluted Net EPS (GAAP) | -0.33 | -0.46 | -0.41 | -0.34 | -0.36 |